A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Public ClinicalTrials.gov record NCT03928743. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
Study identification
- NCT ID
- NCT03928743
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 332 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2019 (Actual)
- Primary completion
- Sep 3, 2021 (Actual)
- Completion
- Aug 8, 2022 (Actual)
- Last update posted
- Sep 25, 2026
2019 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| As0011 50131 | Mesa | Arizona | 85210 | — |
| As0011 50052 | Phoenix | Arizona | 85032 | — |
| As0011 50058 | Phoenix | Arizona | 85037 | — |
| As0011 50062 | Sun City | Arizona | 85351 | — |
| As0011 50060 | Upland | California | 91786 | — |
| As0011 50056 | Sarasota | Florida | 34239 | — |
| As0011 50015 | Hagerstown | Maryland | 21740 | — |
| As0011 50016 | St Louis | Missouri | 63141 | — |
| As0011 50054 | Oklahoma City | Oklahoma | 73103 | — |
| As0011 50020 | Duncansville | Pennsylvania | 16635 | — |
| As0011 50001 | Jackson | Tennessee | 38305 | — |
| As0011 50012 | Memphis | Tennessee | 38119 | — |
| As0011 50057 | Dallas | Texas | 75231 | — |
| As0011 50036 | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03928743, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03928743 live on ClinicalTrials.gov.